Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin in HER2-expressing or amplified head and neck carcinomas
ChiCTR2400084113Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in head and neck cancer (HNC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective response rate. Started May 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on ChiCTR2400084113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084113.